Teletherapy for Stage C Adenocarcinoma of the Prostate

Publisher Website
Google Scholar
Abstract
From 1967-1977, 22 patients with clinical stage C adenocarcinoma of the prostate received external beam radiation therapy with curative intent. The crude rate of survival was 100% at 2 yr and 64% (14 of 22) at 5 yr post-radiation. Metastatic disease developed in 14 patients (64%) 1-5 years after radiation therapy, 5 of whom (23%) died of the disease. Eight patients (36%) who were followed 5-14 years after radiation therapy achieved a status free of disease. When results were analyzed according to grade, 100% of the patients with grade 1 (well differentiated) carcinoma survived free of disease 7-14 yr post-radiation; 40% with grade 2 (moderately differentiated) carcinoma survived free of disease 5-7 yr. Of those patients with grade 3 (poorly differentiated) carcinoma, 0 became free of disease and 63% died of cancer 3-5 yr after radiotherapy. Local control was achieved in 100% of the patients with grade 1 tumors, in 70% with grade 2 disease and in 50% with grade 3 cancer. The degree of tumor differentiation apparently is a major determinant in the response of stage C adenocarcinoma of the prostate to external beam radiation therapy.